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Spinal cord injury (SCI) is a devastating condition that affects many people worldwide. 
Treatment focuses on controlling secondary injury cascade and improving regeneration. 
It has recently been suggested that both the secondary injury cascade and the regenera-
tive process are heavily regulated by microRNAs (miRNAs). The measurement of specific 
biomarkers could improve our understanding of the disease processes, and thereby 
provide clinicians with the opportunity to guide treatment and predict clinical outcomes 
after SCI. A variety of miRNAs exhibit important roles in processes of inflammation, cell 
death, and regeneration. These miRNAs can be used as diagnostic tools for predicting 
outcome after SCI. In addition, miRNAs can be used in the treatment of SCI and its 
symptoms. Significant laboratory and clinical evidence exist to show that miRNAs could 
be used as robust diagnostic and therapeutic tools for the treatment of patients with SCI. 
Further clinical studies are warranted to clarify the importance of each subtype of miRNA 
in SCI management.
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iNTRODUCTiON
Acute spinal cord injury (SCI) is a devastating condition that affects mostly young and active indi-
viduals. It is estimated that approximately 180,000 persons around the world will experience some 
form of traumatic SCI every year (1–3). These injuries are particularly devastating because they can 
result in physically, socially, and financially burdensome consequences, such as quadriplegia and 
paraplegia. Over the past decade, we have gained a much better understanding of the biological 
mechanisms underlying the damage caused by acute SCI. This damage can be divided into two 
phases: primary and secondary (4, 5).
The primary phase of damage after SCI is characterized by the immediate loss of sensory, motor, 
and autonomic functions after a sheer, lacerating, or impact injury to the spinal cord or sudden 
compression of the spinal cord. The initial mechanical damage to the spinal cord primarily disrupts 
gray matter and microvasculature. In contrast, white matter, although damaged in the primary phase, 
is primarily damaged in the secondary phase (4). The secondary phase of damage begins seconds 
Abbreviations: BBB, blood–brain barrier; BMP, bone morphogenic protein; CNS, central nervous system; GFAP, glial fibrillary 
acidic protein; JAK/STAT, Janus-associated kinase/signal transducer and activator of transcription; miRNA, microRNA; ROS, 
reactive oxygen species; SCI, spinal cord injury; SOD, superoxide dismutase.
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after SCI and continues for months after injury. Within seconds 
to minutes of injury, vascular and metabolic disturbances occur 
in the spinal cord. In a matter of minutes to hours, biochemical 
changes lead to altered lipid peroxidation and neurotransmitter 
accumulation. Within hours to weeks, cascades of inflammatory 
cells and evidence of apoptosis occur, and, in weeks to months, 
fiber tract disturbances occur due to demyelination and glial scar 
formation (4–6). The secondary phase of damage is the primary 
target for investigation and clinical therapeutics.
Despite advances in our understanding of the pathways acti-
vated and responsible for secondary injury after SCI, therapeutic 
advances for patients with SCI have lagged behind. So far, the 
“one-size-fits-all” approach to treating SCI has repeatedly come 
up short. Gaps in our knowledge are partially responsible for the 
lack of improvement in therapy. In addition, the inability to iden-
tify a bona fide biomarker that predicts which patients are likely to 
have a good or poor outcome after SCI has hindered delivery and 
implementation of new therapies. Because no two SCIs are alike, 
treatment approaches should be tailored to the nature, quality, 
and duration of the injury. Novel approaches to SCI treatment 
will thus involve a shift toward personalized medicine.
In recent years, investigators have begun to document the 
potential effects that microRNA (miRNA) sequences may have 
on the regulation of the processes involved in SCI (7–9). The 
miRNA sequences are small, unique, non-coding RNA fragments 
that form hairpin structures averaging 22 nucleotides in length. 
They are produced in the nucleus by RNA polymerase II and 
processed by a variety of proteins before entering the cytoplasm 
as pre-miRNA. In the cytoplasm, the enzyme coded for by the 
gene, dicer 1 ribonuclease type III, or DICER1, processes the 
pre-miRNA duplex into a single-stranded miRNA sequence. This 
single-stranded miRNA sequence is incorporated into an RNA 
silencing complex that then binds to an mRNA sequence to carry 
out a negative regulatory effect by either degrading or blocking 
translation in the targeted mRNA (8, 10, 11). This regulatory 
system has a powerful effect on mRNA levels, and, as a result, it 
influences protein expression levels (12). Because miRNAs do not 
need a perfectly complementary sequence to act upon an mRNA, 
investigations have found that a single miRNA sequence is able to 
target up to 200 mRNA transcripts (11).
The miRNAs have a powerful and important influence on 
the protein profile of a given cell. Since the discovery of the 
first miRNA sequence in 1993, thousands of unique miRNA 
sequences that play key regulatory roles in the human body have 
been identified (8). In particular, miRNAs have been identified as 
playing an important role in regulating neurogenesis and cortical 
development (13). The management of SCI will be dramati-
cally improved if novel pathophysiological mechanisms of SCI 
and sensitive biomarkers to monitor them can be determined. 
Alterations in extracellular RNAs could be used to identify 
regulators of secondary injury cascades, and overall changes in 
RNA concentrations could be used to stratify patients into risk 
categories for secondary injury and could be predictive of patient 
outcomes – a form of personalized medicine for patients suffering 
from the effects of SCI.
In this article, we review the regulatory role of miRNAs in 
the cascade of events, after an acute SCI. We also discuss their 
temporal and spatial expression, as well as their potential role 
as therapeutic agents in the personalized treatment of patients 
with SCI.
SCi PATHOPHYSiOLOGY AND miRNAs
Astrogliosis
Normally, astrocytes regulate central nervous system (CNS) 
homeostasis by maintaining the blood–brain barrier (BBB) and 
the blood–spine barrier, directing neuronal migration, differentia-
tion, and development, and providing materials for axonal growth 
or regeneration (14). When a patient suffers a significant injury 
to the spinal cord and suffers the effects of secondary trauma, 
the area near the injury undergoes astrogliosis. In the acute 
stages of astrogliosis (at approximately the third day after injury), 
hypertrophic astrocytes expressing glial fibrillary acidic protein 
(GFAP) and vimentin (VIM) surround the lesion site, where 
they keep out inflammatory leukocytes, release antioxidants, and 
initiate repair of the blood–spinal cord barrier. These effects are 
both protective and beneficial. In later stages of astrogliosis (at 
approximately 4–6  weeks after injury), astrocytes change from 
hypertrophic to hyperplastic, forming a glial scar by expressing 
chondroitin sulfate proteoglycans. This is a detrimental process 
that compresses the entire lesion site and prevents the beneficial 
self-rehabilitating and protective actions that were present in the 
acute hypertrophic phase (Table 1) (7, 14–19).
The process of astrogliosis has been shown to be associ-
ated with miRNAs, which play a pivotal role in the shift from 
hypertrophy to hyperplasia (7, 14–19). The miRNA miR-21 is 
highly expressed in astrocytes near and at the lesion site dur-
ing astrogliosis, but not elsewhere (7). In addition, miR-21 is 
directly responsible for the shift from hypertrophy to hyperpla-
sia, where it suppresses GFAP and VIM (Figure 1). The miR-21 
is governed by bone morphogenic protein (BMP) signaling 
via the signal transducer and activator of the transcription 3 
gene, STAT3 (14–16, 19). Specifically, the BMP receptor type 
1A and 1B genes, BMPR1A and BMPR1B, control astroglio-
sis by regulating miR-21 in opposing directions. BMPR1A 
downregulates miR-21 signaling, while BMPR1B upregulates 
it (7,  15,  16). These regulatory genes have become a target of 
interest for developing therapeutics. Knockout mice with 
suppressed miR-21 signaling maintain astrocyte hypertrophy, 
correlating with smaller lesion sites, less demyelination, greater 
axon regeneration, and an overall lower inflammatory response 
(7, 15, 16). Future treatment modalities could be geared toward 
preventing the shift to hyperplastic astrogliosis. The targets of 
these potential treatment modalities include the final processing 
of pre-miR-21 to its mature form, the formation of chondroitin 
sulfate proteoglycans, RNases that could suppress miR-21, and 
the suppression of BMPR1B.
Additional miRNAs involved in astrogliosis include miR-145, 
which is expressed in gray matter astrocytes during acute astro-
gliosis but which increases expression in astrocytes during the 
shift to hyperplasia. It has been shown to control the astrocytic 
cytoskeleton, where it affects cell growth and migration, in addi-
tion to negatively regulating GFAP and the cell growth gene, MYC 
(c-myc) (Table 1; Figure 1) (17). Strickland et al. have shown that 
TAbLe 1 | Functions of miRNAs in spinal cord injury pathophysiologya.
miRNA 4 h 12 h 1 day 3 days 4 days 7 days 14 days ≥30 days Regulation Target genes Function
miR-9 (20)      miR-9  MCPIP1  Inflammation,  apoptosis
miR-17-5 (21)  miR-17-5p  CDKN1A,  RB1  Astrocyte proliferation
miR-20 (7, 22)       miR-20a  NEUROG1  Oxidative stress,  
 functional recovery
miR-21 (8, 9, 15, 16, 
18, 23–31)
        miR-21  GFAP  Astrogliosis
 miR-21  FASLG,  PTEN  Apoptosis
 miR-21  MTOR  Axon sprouting
 miR-21  CACNA1C,  
 CACNA2D1,  
 CACNAB1
 Calcium signaling, 
 neurotransmission
 miR-21  Neuropathic pain
 miR-21  Functional recovery
miR-29b (22)       miR-29b  BH3  Apoptosis
miR-103  
(23, 24, 32–34)
   miR-103  CACNA1C,  
 CACNA2D1,  
 CACNAB1
 Neuropathic pain




 miR-103  Inflammation
miR-124 (35–39)       miR-124  PTBP1  Neuronal expression, 
 functional recovery, 
 apoptosis
miR-125b (9, 40)  miR-125b  Axonal regeneration
miR-126 (41)     miR-126  VCAM1  Immune cell infiltration
 PIK3R2  Apoptosis
 SPRED1  Cell growth,  angiogenesis
miR-145 (17, 24, 42)        miR-145  GFAP,  MYC  Astrogliosis
 miR-145  SOD2  Oxidative stress
miR-146 (7, 18, 24, 
43, 44)
   miR-146  IRAK1, TRAF6  Inflammation
 miR-146  Astrogliosis
miR-146a (7, 18, 
43, 44)
    miR-146a  IRAK1  Astrogliosis
 miR-146a  CASP3,  
 FAS/CD95
 Apoptosis
 miR-146a  IL6,  COX2  Inflammation
 miR-146a  IL6,  COX2  Inflammation
 miR-146a  CASP3,  FAS/
CD95
 Apoptosis
miR-155 (45, 46)      miR-155  SOCS1  IL-17 Expression,  
 Th17 differentiation miR-155  GAP43,  NEFH
miR-181 (47, 48)  miR-181  TNF  Inflammation
 miR-181  Astrogliosis
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(Continued)
FiGURe 1 | Schematic for astrogliotic effects of miRNA expression 
after SCi. The end result is a downregulation of astroglial swelling, and 
upregulation of cell division. CDK6, cyclin-dependent kinase 6; CDKN1A 
(P21), cycline-dependent kinase inhibitor 1A; MYC, V-myc avian 
myelocytomatosis viral oncogene homolog; GFAP, glial fibrillary acidic 
protein; IRAK1, interleukin-1 receptor-associated kinase-1; MBP, myelin 
basic protein; RB1, ginsenoside Rb1; VIM, vimentin. Used with permission 
from Barrow Neurological Institute, Phoenix, AZ, USA.
miRNA 4 h 12 h 1 day 3 days 4 days 7 days 14 days ≥30 days Regulation Target genes Function
miR-195 (49)  miR-195  IL1B;  TNF  Neuropathic pain
 miR-195  IL1B;  TNF  Neuropathic pain
miR-199a-3p (27)  miR-199a-3p  MTOR  Axon regeneration
miR-200c (50)     miR-200c  FAP-1  Apoptosis
miR-210 (51)  miR-210  Axon growth,  remyelination, 
 angiogenesis,  
 functional recovery
miR-218 (52)      miR-218  JAK, STAT3, 
SOCS3
 Pain behavior,  inflammation
miR-219 (53)  miR-219  ELOVL7  Demyelination
miR-223 (7, 54)     miR-223  GRIA2,  BAX, 
CASP3,  BCL2
 Apoptosis,  angiogenesis, 
 functional recovery
 miR-223  Inflammation
miR-320 (55)  miR-320  HSP20  Neuroprotection,  
 functional recovery
miR-381 (56)  miR-381  HES1  Neuronal differentiation,  
 glial cell differentiation
aAn up arrow () indicates upregulation; a down arrow () indicates downregulation.
TAbLe 1 | Continued
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approximately 30 miRNAs are altered by SCI (18). They report 
that miR-146a works with miR-21 to drive astrocyte hyperplasia, 
while miR 129-1 and miR 129-2 both inhibit the cyclin-dependent 
kinase gene, CDK6, and therefore prevent cell growth (Figure 1). 
The knockdown of these genes in SCI suggests a more conducive 
environment for hyperplastic astrogliosis (18).
In 2014, Hong et al. speculated that miR-17-5p is somehow 
involved in p21 (CDKN1A) regulation and promotes astroglial 
cell proliferation after injury by way of DICER1 (Table 1) (21). 
Knocking out DICER1 in mice caused miR-17-p5 to decrease 
GFAP expression while maintaining cell proliferation (Figure 1). 
This effect suggests that DICER1 and miR-17-5p are directly 
involved in the maturation and proliferation of astrocytes. The 
knockdown of these components delayed astrocyte maturation 
and ultimately caused a failure to respond to the SCI cascade. 
These data further support the idea that selective manipulation of 
the astrogliotic response to SCI may be a key therapeutic strategy 
for SCI (21).
Apoptosis
Apoptosis, or programed cell death, is a hallmark of SCI. 
Apoptosis can affect all cell types in the spinal cord, including 
glial cells. This is important when considering that SCI induces 
miRNA expression to either upregulate or downregulate apop-
totic genes, depending on the target (Table  1) (7, 14, 23–25, 
57–63). Among the miRNAs involved in this process, miR-21 
has been shown to be one of the most dysregulated miRNAs after 
SCI (24, 25). As mentioned above, the shift from hypertrophy 
to hyperplasia in astrogliosis is heavily governed by miR-21, 
and the suppression of miR-21 is known to cause apoptosis. The 
miR-21 is a downregulator of the Fas ligand gene, FASLG, and 
the phosphatase and tensin homolog gene, PTEN, both of which 
promote apoptosis (Table 1; Figure 2) (7, 25, 58, 63). Strickland 
et  al. demonstrated that miR-21 was significantly upregulated 
4  days after SCI, only to be downregulated, relatively, by day 
14 (18). This effect explains the transition from hypertrophy to 
hyperplasia that occurs 4–10 days after injury. This trend paral-
lels that described by Liu et al., who reported that miR-21 levels 
were not significantly elevated at 10 days after SCI, but were still 
somewhat elevated (63). Although the suppression of miR-21 
FiGURe 2 | Apoptotic effects of miRNA expression after SCi. The result 
is apoptotic signaling. BAX, BCL2-associated X, apoptosis regulator; BCL2, 
B-cell chronic lymphocytic leukemia/lymphoma 2; BH3, BCL2 homology 
domain 3; CASP3, caspase 3; CD95, also known as FAS receptor (cell 
surface death receptor), apoptosis antigen 1, and tumor necrosis factor 
receptor superfamily member 6; FAP1, Fas-associated phosphatase-1; 
GRIA2, glutamate ionotropic receptor AMPA (α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid) type subunit 2; MCPIP1, monocyte chemotactic 
protein-induced protein 1; PIK3R2, phosphoinositide-3-kinase regulatory 
subunit 2; PTEN, phosphatase and tensin homolog. Used with permission 
from Barrow Neurological Institute, Phoenix, AZ, USA.
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appears to have many beneficial effects related to astrogliosis, 
neuronal cell death has the opposite effect. Suppressing miR-21 
using antagomir-21 increases neuronal deficits and lesion size 
in spinal cord tissue at 28 days after SCI (25). This effect is in 
contrast to findings of the previously mentioned study that found 
that the inhibition of miR-21 causes smaller lesion sizes and 
more effective recovery at 1–2 weeks after injury. However, both 
sets of data may be correct within their respective time frames.
Like miR-21, miR-146a is antiapoptotic as well as anti-
inflammatory. However, it appears that, while miR-21 decreases 
in expression after 14 days, miR-146a remains constant in upreg-
ulation (Table 1) (18). This constant upregulation may indicate 
that miR-146a maintains the antiapoptotic state after the acutely 
reacting miR-21 has downregulated. In addition to miR-21 
and miR-146a, miR-9 controls apoptosis by directly regulating 
the monocyte chemotactic protein-induced protein 1 gene, 
or MCPIP1, which is a known proapoptotic and macrophage-
activating gene (Figure 2) (20). This postulated mi-9-controlled 
apoptosis is supported by the observation that, between days 
1 and 7 after SCI, miR-9 was significantly downregulated in 
ventral horn motor neurons whereas MCPIP1 was upregulated 
at the lesion site. However, by day 7, the miR-9 expression had 
increased, suppressing the expression of MCPIP1. Interestingly, 
MCPIP1 also promotes GFAP, which is expressed by reactive 
astrocytes during astrogliosis (20). Thus, miR-9 appears to have 
a bimodal effect on SCI, such that its downregulation during 
acute stages allows for the expression of GFAP and the activation 
of astrocytes, while its upregulation at day 7 suggests a neuropro-
tective role of ventral motor horn cells. Considering that miR-21 
plays a strong antiapoptotic role during acute SCI, miR-9 may 
work the opposite of miR-21, such that the downregulation 
of one is countered by the upregulation of the other. Further 
research is needed to observe the expression of miR-9 beyond 
7 days in order to elucidate the relationship between these two 
miRNAs.
Other studies have shown that miR-223 is expressed in 
human and mouse hematopoietic systems (64). In SCI, miR-223 
is temporally expressed, with increased peaks of expression at 1, 
3, 7, and 14 days after SCI. Antagomir-223 treatment after SCI 
resulted in significantly lowered apoptotic cells, coinciding with 
downregulated BAX and CASP3 and upregulated BCL2. This 
treatment preserved spinal cord tissue and significantly increased 
scores on the Basso, Beattie, and Bresnahan locomotor scale as 
early as 3 days after SCI (Table 1; Figure 2) (64).
In general, apoptosis after SCI is caused by either downregu-
lation of miRNAs that target proapoptotic genes, such as caspase 
family genes, or upregulation of miRNAs that target antiapop-
totic genes, such as BCL2 or MYC (Table  1) (7, 23, 60–63). 
These regulatory effects provide multiple avenues for potential 
therapeutic strategies, which involve managing the balance of 
proapoptotic and antiapoptotic miRNAs. One such strategy was 
described by Liu et  al. in 2010; in their study, a 5-day cycling 
exercise regimen within the first 10 days of injury significantly 
altered miRNA expression in mice (63). Their study showed that, 
with exercise, the antiapoptotic agents, miR-21 and BCL2, are 
upregulated, while proapoptotic agents miR-15b, CASP7, and 
CASP9 are downregulated. These authors posit that exercise 
after SCI may stimulate beneficial antiapoptotic effects through 
the influence of miR-21 on the v-akt murine thymoma viral 
oncogene homolog 1 gene, AKT1, and on phosphatidylinositol 
triphosphate (Table 1) (63). Another potential therapy strategy 
is posttraumatic hypothermia and antisense silencing. Truettner 
et al. demonstrated that specific miRNAs are sensitive to post-
traumatic hypothermia in brain lesions, which downregulates 
their apoptotic effects (59).
endogenous Antioxidant Systems and 
Neuroprotection
Another secondary effect of SCI, traumatic brain injury, or 
ischemia is the presence of reactive oxygen and nitrogen species 
(65). These molecules function to destroy cell and DNA structure, 
interfere with important cellular processes, and ultimately cause 
unintended cell death. The production of free radicals is caused by 
cytotoxic concentrations of glutamate (65, 66). During astroglio-
sis (the hypertrophic state), astrocytes build barriers against these 
reactive species, releasing antioxidants by way of the superoxide 
dismutase (SOD) family of genes and diverting glutamate excito-
toxicity away from oligodendrocytes and neurons (14). However, 
during an oxidative crisis, miRNAs appear to exhibit functions 
that hinder the body’s protective response. For example, it has 
been observed that miR-21 strongly influences reactive oxygen 
species (ROS)-induced apoptosis during oxidative stress (67). 
When miR-21 was silenced, ROS-induced cell death was reduced 
in spinal cord neurons. The effect on spinal cord cells by miR-21 
was analogous to that of free radicals (Table 1) (67). These data 
suggest that the antiapoptotic effects of miR-21 overexpression do 
not apply to neurons.
One example is miR-486, which targets the neuronal dif-
ferentiation 6 gene, NEUROD6, a trigger for heat shock proteins. 
When miR-486 is knocked down, the expression of NEUROD6 
caused increased clearance of ROS and lower levels of proin-
flammatory agents (Figure 3) (7, 68). The neurogenin 1 gene, 
FiGURe 4 | inflammatory effects of miRNA expression post SCi. While 
downregulation of miR-146 and miR-181 leads to increased inflammation, 
upregulation of miR-126 leads to decreased extravasation of immune cells 
into the CNS. COX2, cyclooxygenase 2; IL6, interleukin 6; IRAK1, IL-1R-
associated kinase 1; TRAF6, TNFR-associated factor 6; TNF, tumor necrosis 
factor; VCAM1, vascular cell adhesion molecule 1. Used with permission 
from Barrow Neurological Institute, Phoenix, AZ, USA.
FiGURe 3 | Antioxidation and neuroprotection of central nervous 
tissue. After SCI, increased expression of three miRNAs results in a loss of 
neuroprotective metabolites, causing reactive oxygen species-induced 
apoptosis. NEUROD6, neurogenic differentiation 6; NEUROG1, neurogenin 1; 
SOD2, superoxide dismutase 2. Used with permission from Barrow 
Neurological Institute, Phoenix, AZ, USA.
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NEUROG1, is a differentiation factor in embryogenesis whose 
overexpression in progenitor cells heavily favors neuronal dif-
ferentiation. It is generated from the same precursor factor that 
produces NEUROD6 (Table 1) (7, 69, 70). The miRNA miR-20a, 
which is overexpressed in SCI, targets NEUROG1 and prevents 
neuronal regrowth in the lesion site, presumably contributing 
to the motor neuron degeneration and apoptosis that follows 
spinal cord trauma (Figure  3) (22). A therapy that blocked 
miR-20a or that introduced exogenous NEUROG1 would 
result in regeneration of neurons and improved functional 
deficit, making miR-20a a prime candidate for therapy (7, 
68). Conversely, miR-29b is implicated in having antiapop-
totic effects in ischemia by repressing the apoptotic BH3 gene 
(Table  1) (22). A treatment strategy could take advantage of 
these effects by manipulating miR-20a and miR-29b in tandem 
to treat SCI (22).
Dharap et al. demonstrated that miR-145 targets SOD2 after 
experiments with antagomir-145 led to higher levels of SOD2 
expression in mice with cortical ischemia (Table  1; Figure  3) 
(42). A similar pattern of expression has been observed in 
cortical ischemia and in plexus root avulsion, such that neurons 
ipsilateral to the lesion site express the highest levels of miRNA 
(71). This relationship suggests a unilateral miRNA response to 
SCI injuries. However, the contralateral side shows microglial 
activation in what is hypothesized to be a spillover of the changes 
observed on the opposite side (42, 71). Recent research has 
shown that miR-200c is another miRNA significantly altered 
by apoptotic events after SCI, as miR-200c upregulation was 
observed alongside the downregulation of its target, Fas-
associated phosphatase-1 (FAP1), and, ultimately, the induction 
of FAS signaling (50).
inflammation
Although inflammation is part of the natural healing process, 
much of medicine is geared toward minimizing it or eliminat-
ing it, altogether. Inflammation is constantly regulated by the 
body’s innate immune system (43). In the setting of SCI, the 
role of inflammation is that of deleterious effects causing tissue 
compression and excessive cell death. One of the main functions 
of astrogliosis is to minimize inflammatory reactions in and 
around the lesion site to minimize the spread of secondary dam-
age beyond the initial point of trauma. In SCI, the expressions 
of the various miRNAs that help regulate the body’s inflamma-
tory processes are altered and are thus an important target for 
potential therapies.
The miRNA miR-146a is described above as being intimately 
cooperative with miR-21 and involved in the shift from astroglial 
hypertrophy to hyperplasia. Studies have shown that miR-146a 
is highly expressed in spinal astrocytes during SCI. It targets the 
proinflammatory enzyme cyclooxygenase-2 (COX-2) and the 
proteins encoded by the genes, IL1B and IL6 (Table 1; Figure 4) 
(7, 18, 43, 44). In previous studies on temporal lobe epilepsy, 
astrocytes were highly expressed during latent periods, in rela-
tion to high levels of miR-146a (43, 44). Furthermore, these 
studies showed that miR-146a (in macrophages) works in cyclic 
feedback with the transcription factor NF-κB, via interleukin 1 
receptor-associated kinase 1 gene (IRAK1) and the TNF recep-
tor-associated factor 6 gene (TRAF6). Activation of the NF-κB 
pathway in macrophages upregulates miR-146a, resulting in 
the downregulation of IRAK1 and TRAF6 pathway constituents 
(Table 1) (43, 44). A correlation can be drawn between these phe-
nomena and SCI, in which miR-146a levels peak and astrocytes 
increase anti-inflammatory activity. However, although some 
research on hyperplastic glial scars attributes functional deficit 
to miR-146a overexpression, other research deems miR-146a 
valuable in preventing the deleterious effects of inflammation 
(43, 44). Therefore, while miR-146a is beneficial in the schema of 
acute anti-inflammatory treatment, overexpression of miR-146a 
beyond the subacute stages of SCI seems to become deleteri-
ous, as seen with miR-21. The Notch-1 pathway may exhibit a 
potential therapeutic role in SCI. Notch-1 can lead to malignant 
astrocyte proliferation, but it is inhibited by miR-146 (44). This 
relationship is important, considering that previous research 
has implicated miR-146a in the negative effects of glial scar 
formation, which supports the idea that miR-146a attenuates the 
hyperplastic effects of miR-21 (44). Manipulation of miR-146a 
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after SCI may allow for an ideal balance of anti-inflammatory and 
antihyperplastic effects, which may lead to improved healing and 
reduced scarring.
The miRNA miR-181 is expressed in macrophages, monocytes, 
and astrocytes (47, 48). It is a well-known anti-inflammatory 
agent because its overexpression leads to the suppression of 
proinflammatory cytokines, such as IL-1β, IL-6, IL-8, and TNFα. 
Furthermore, miR-181 suppresses HMGA-1, a proinflammatory 
factor that is regulated by COX2 and STAT3 (Table 1; Figure 4) 
(47, 48). However, miR-181 expression is decreased in SCI, 
which would allow for an increased inflammatory response 
after SCI. This situation is confounding in light of the strong 
anti-inflammatory signals that astrocytes send out during acute 
astrogliosis, which may mean that miR-181 is less functional 
in SCI than it is in Alzheimer’s disease or cortical ischemia, as 
research suggests (47). Another miRNA, miR-223, is shown to 
be overexpressed near areas of increased neutrophil aggregation, 
which suggests that miR-223 is implicated in neutrophil hom-
ing. This process counters that of hypertrophic astrocytes, which 
attempt to rid the central lesion of inflammatory cells during the 
subacute phase of astrogliosis (7, 54). The expression of miR-223 
is time-dependent. It peaks twice at 12  h and 3  days after SCI 
and significantly decreases after that. This coincides with peak 
neutrophil expression 1 day after SCI, followed by downregula-
tion 5 days after SCI (Table 1) (7).
In 2015, Hu et al. demonstrated that miR-126 is highly involved 
in attenuating inflammation, alongside angiogenesis and func-
tional recovery (41). An agonist method showed that, in mice 
treated with exogenous miR-126, the expression of biomarkers 
for extravasated leukocytes and macrophages (CD45 and CD68, 
respectively) were downregulated. This observation implicates 
miR-126 as a potential therapeutic strategy for SCI, because it is 
downregulated in SCI. The miR-126 targets VCAM1, which is a 
receptor on endothelial cells for leukocyte homing. VCAM1 was 
shown to be downregulated in agomir-126-treated mice (Table 1; 
Figure 4) (41).
PROCeSSeS OF SCi ReCOveRY 
ReGULATeD bY miRNA
Neuroplasticity
One of the main clinical concerns after SCI is the potential for 
functional recovery. Chances for recovery after complete trans-
verse spinal cord lesions are slim. When spinal cord lesions are 
incomplete, the chances of recovery are greater, in part due to 
the neuroplasticity of the cortical and subcortical neurons and 
glial cells (72). Chronic SCI can cause regional changes in glu-
cose metabolism, revealed on positron-emission tomography 
as larger areas of activation in somatosensory regions for SCI 
patients compared with normal patients (72). Certain miRNAs 
are expressed in the brain, which indicates that miRNAs could 
function in both tissue development and higher brain function. 
In fact, researchers have compiled data that explain the array of 
morphological functions that miRNAs perform in the CNS (73, 
74). An example of the functions of miRNAs in neuroplasticity 
is miR-133b in stroke. Xin et  al. conducted an experiment in 
which mice with induced middle cerebral artery occlusion were 
infused with three types of modified murine mesenchymal 
stem cells: naïve, miR-133b(+), and miR-133b(−) (74). Their 
results showed that the greatest functional recovery occurred in 
subjects with the miR-133b(+), while no recovery occurred in 
miR-133b(−) subjects. Furthermore, it was determined that the 
miR-133b(+) mesenchymal stem cell group also exhibited the 
greatest increase in neuronal plasticity and neurite remodeling 
in the ischemic zone. Exosome-mediated transfer of mesenchy-
mal stem cells occurred in greatest numbers to neurons and 
astrocytes, where miR-133 downregulated connective tissue 
growth factor expression (74). Connective tissue growth factor 
is colocalized with GFAP, which is highly expressed during 
hypertrophic astrogliosis. Selective expression of GFAP and not 
connective tissue growth factor during astrogliosis could poten-
tially function to maximize the beneficial effects of hypertrophic 
astrocytes.
Axon Regeneration and Remyelination
In mammals, regeneration is the main difference in recovery 
between a peripheral nervous system injury and a CNS injury. 
Peripheral nervous system injuries are more likely to self-repair, 
whereas CNS injuries do not self-repair. Peripheral nervous 
system axons have one Schwann cell per myelin sheath (equaling 
many Schwann cells per single axon), but CNS axons have one 
oligodendrocyte per several sheaths. Thus, oligodendrocytes are 
far more indispensable than Schwann cells. Therefore, the CNS is 
capable of regeneration, so long as the oligodendrocytes remain 
intact, which is often not the case in SCI, when trauma, ROS, 
inflammation, and other factors destroy any neuron or glial cell 
in their path.
Recent research shows that it may be possible to rebuild 
oligodendrocytes and to repair axonal damage after SCI using 
miRNAs. Park et al. regenerated axons after optic nerve injury 
by deleting the phosphatase and tensin homolog gene, PTEN, 
and thereby upregulating the mechanistic target of rapamycin 
gene, MTOR, in the adult retinal ganglion cells of adult mice 
(26). As a follow-up to this article, Liu et al. extrapolated on 
their earlier work, in which early exercise after SCI correlated 
with upregulation of miR-21 and downregulation of miR199a-
3p (Table 1) (27). According to Liu et al., the upregulation of 
miR-21 and the downregulation of miR199a-3p with exercise 
lead to the subsequent downregulation of PTEN and the 
upregulation of MTOR, the respective targets of miR-21 and 
miR-199a-3p (Figure  5) (27). This evidence strengthens the 
idea that bimodal control of neuronal apoptosis and axon 
degeneration can be achieved through these two miRNAs 
(Table 1) (26, 27).
Letzen et al. have shown that there are many miRNAs involved 
in the growth and proliferation of oligodendrocytes (28). 
Multiple oligodendrocyte-related miRNAs can be regulated by an 
oligodendrocyte-specific dicer. Research shows that mutant mice 
lacking the oligodendrocyte-specific dicer suffer brain demyeli-
nation and axonal impairment (Table 1) (53). These traits were 
found in addition to severe astrogliosis, inadequate antioxidant 
systems, and increased inflammation in the brain. Of the three 
major miRNAs downregulated by oligodendrocyte-specific dicer 
FiGURe 6 | Neuroregenerative effects of miRNA expression. Multiple miRNA are responsible for neuron growth, regeneration, and remyelination. Upregulation 
of miR-126 and miR-124 leads to downregulation of negative regulators of growth signaling, while the downregulation of many other miRNA induce the expression 
of pro-growth factors. BDNF, brain-derived neurotrophic factor; CDC42, cell division protein 42; PTBP1, polypyrimidine tract-binding protein 1; SPRED1, 
Sprouty-related EVH1 (enabled/vasodilator-stimulated phosphoprotein homology 1) domain containing 1. Used with permission from Barrow Neurological Institute, 
Phoenix, AZ, USA.
FiGURe 5 | Axon regeneration and remyelination by miRNA 
expression. Exercise is known to decrease inflammation and thus increase 
regeneration of axon structures. Meanwhile, downregulation of miR-219 
showed to induce demyelination after SCI. ELOVL7, elongation of very long 
chain fatty acids protein 7; MTOR, mechanistic target of rapamycin; PTEN, 
phosphatase and tensin homolog; RHOA, ras homolog gene family, 
member A. Used with permission from Barrow Neurological Institute, 
Phoenix, AZ, USA.
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inhibition, miR-219 is observed to have the greatest contribution to 
astrogliosis, oxidative stress, and inflammation. Downregulating 
miR-219 leads to the dysregulation of its target gene, elongation 
of very long chain fatty acids protein 7 gene, ELOVL7, causing 
lipid accumulation in the white matter of the brain (Figure 5) 
(53). If miR-219 can be identified as playing an important role in 
the spinal cord, a potential therapy may be found in upregulating 
its expression after SCI.
The expression patterns of miRNA-125b help explain the 
discrepancies between the regenerative powers of reptiles and 
mammals (40). Reptiles are capable of regenerating CNS tissue 
after excision, whereas mammals are not. In the axolotl salaman-
der, expression of miR-125 is precisely controlled, so that excess 
expression causes erratic axonal growth with incomplete recon-
nection, and reduced expression causes inhibition of axonal 
regeneration. In addition, glial scars are not seen after SCI in 
the axolotl, as they are in rats. This study shows that mammals 
could potentially benefit from increased miR-125 expression 
after SCI (40).
As mentioned above, the miRNA miR-133 was found to have 
a beneficial effect on neuroplasticity. Yu et al. demonstrated that 
miR-133 exhibits axonal regenerative properties in zebrafish, 
where it targets the ras homolog family member A gene, RHOA, 
whose product is a GTPase that inhibits neural regeneration and 
functional recovery in mammals and fish (Figure 5) (75). Another 
miRNA, miR-210, has been implicated as a possible therapeutic 
strategy for SCI, because it has been correlated with axon growth, 
in addition to neovascularization, astrogliosis, and myelination. 
The miR-210 suppresses the protein tyrosine phosphatase, non-
receptor type 1 gene, PTPN1, and the ephrin-A3 gene, EFNA3, 
which has been shown to provide these benefits, leading to 
functional recovery in mice (Table 1) (51). As mentioned above, 
the miRNA miR-9 controls apoptotic factors during acute and 
subacute SCI (see Apoptosis). In addition to these effects, miR-9 
has also been shown to play a role in suppressing Schwann cell 
migration, a critical step in neuroregeneration. Because of this 
ability, Xu et al. suggest that lower levels of miR-9 are needed dur-
ing the acute stage of SCI to allow for adequate axon regeneration 
and remyelination (Table 1) (20).
Neuron Regeneration
Even though the CNS is restorable after injury if oligodendrocytes 
are intact, neuron degeneration is a problem after SCI, because, so 
far, neurons cannot be brought back. However, miRNA therapy 
offers an avenue to achieve neuron regeneration.
A bioinformatics study by Liu et al. (76) demonstrated that 
the body attempts to preserve neurons and to stimulate neuron 
growth, regeneration, and remyelination through the expres-
sion of a handful of genes through the action of miRNAs. 
Genes such as the brain-derived neurotrophic factor gene, 
BDNF, and the cell division cycle 42 gene, CDC42, are genes 
positively influencing SCI self-repair. The expression of these 
genes is inversely related to a large list of miRNAs that are 
thought to target them (BDNF can be influenced by miR-183, 
miR-195, miR-30a, miR-182, miR-381, miR-300-3p, and miR-
325-5p; and CDC42 can be influenced by miR-185, miR-329, 
miR-340-5p, miR-381, and miR-383) (Table  1; Figure  6). 
Additionally, several miRNAs are thought to promote these 
two genes, and a balance between these two sets of miRNAs 
may play a critical role in self-repair (76). miR-124 restores 
FiGURe 7 | miRNA expression leading to functional recovery after 
SCi. Downregulation of miR-320 leads to neuroprotective effects, while 
upregulation of miR-21 and miR-155 induce neuronal recovery and T-cell 
expression, respectively. IL17, interleukin 17; HSP20, heat shock protein 20; 
SOCS1, supressor of cytokine signaling 1; Th17, T helper cell 17. Used with 
permission from Barrow Neurological Institute, Phoenix, AZ, USA.
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neurons and recovers function (35). In SCI, miR-124 is down-
regulated continuously through the first 7 days after SCI at and 
around the lesion site (Table 1; Figure 6) (36, 37). Zou et al. 
observed that mesenchymal stem cells derived from bone mar-
row do not naturally express adequate levels of miR-124, so 
they transfected mesenchymal stem cells with miR-124, trans-
planted those cells into injured rat spinal cords, and observed 
that the transfected mesenchymal stem cells had significant 
neuronal expression (35). The transplanted rats had higher 
scores on the Basso, Beattie, and Bresnahan locomotor scale, 
and their functional recovery was higher, but their apoptosis 
was lower. These data suggest that the overexpression of miR-
124 is linked with neural cell development and regeneration 
in SCI (35). miR-124 acts by targeting the polypyrimidine 
tract-binding protein 1 gene, PTBP1, which is a regulatory 
gene for neural precursor cell differentiation (36, 37). Xu 
et al. conducted a similar experiment; (38) however, they used 
neural stem cells from bone marrow-derived mesenchymal 
stem cells. After conducting a very similar experiment to that 
of Zou et al. (35), Xu et al. also observed significantly greater 
motor function outcomes in rats with SCI (38). It might be 
of interest for future studies to evaluate the time-dependence 
of therapy with miR-124 in order to understand its effects on 
astrogliosis since miR-124 selectively proliferates neurons 
over glial cells. Other studies have implicated miR-124 in 
reducing CNS inflammation by downregulating macrophage/
microglia expression, while maintaining astrocytic expression, 
thus maintaining the anti-inflammatory effects of astroglial 
scarring (39).
Hu et al. made similar observations with miR-126, when they 
demonstrated that the injection of miR-126 increased protection 
of spinal cord motor axons (41). Typically, miR-126 is signifi-
cantly downregulated by SCI, but upregulation therapy reversed 
this expression pattern, causing a decrease in apoptosis of motor 
neurons and an increase in functional motor recovery as long as 
28 days after SCI (41). One of the main targets of miR-126, the 
phosphoinositide-3-kinase regulatory subunit 2 gene (PIK3R2) 
is a negative regulator of the phosphoinositide 3-kinase (PI3K) 
pathway, and thus, the apoptotic pathway. Another target is the 
sprouty-related, EVH1 domain-containing 1 gene (SPRED1), 
which is a negative regulator of growth factor signaling (Table 1; 
Figure 6) (41).
Neural stem cells have been a therapeutic strategy focus. 
Shi et  al. demonstrated that miR-381 regulates neural stem 
cell differentiation (56). They found that overexpression of 
miR-381 in neural stem cells causes the expression of the hes 
family bHLH transcription factor 1 gene, HES1, which triggers 
proliferation and differentiation into neurons, but which inhibits 
differentiation into astrocytes (Table  1). These results suggest 
that manipulating neural cell differentiation should be done in a 
time-dependent manner, depending on the length of time since 
the patient’s injury. Introducing miR-381-infused neural stem 
cells and inhibiting astrocyte proliferation during acute stages 
of SCI may inhibit the beneficial effects of astrogliosis during 
acute stages. Conversely, infusing miR-381 during subacute or 
chronic stages may be of great benefit in reversing the cell death 
seen later.
Functional Recovery
The main objective in researching SCI is ultimately to help 
patients achieve superior functional recovery. Importantly, 
investigators often achieve functional recovery in experiments on 
miRNAs in SCIs (7, 15, 16, 25, 29, 30, 35, 38, 47, 51, 72, 74, 75, 77, 
78). Recent evidence shows miRNAs may be helpful for repairing 
hind limb functionality in murine SCI (55). In this study, inhibi-
tory treatment of miR-320 markedly improved motor scores, 
while upregulating the expression of phosphorylated HSP20, a 
gene that protects against ischemia-reperfusion injury (Table 1; 
Figure 7) (55).
A view not previously mentioned is observed with vimentin 
in scar formation. GFAP and vimentin are factors expressed in 
hypertrophying astrocytes, and their expressions are downregu-
lated by miR-21 during the shift toward hyperplastic astrogliosis 
(14–16). In contrast, Qian et al. demonstrated highly expressed 
vimentin levels in spinal cord scar tissue as a result of astrocytic 
hyperplasia. In fact, the knockdown of vimentin in scar tissue 
showed significant improvement in locomotor function, while 
overexpression of vimentin showed the opposite (Table  1; 
Figure  7) (77). This result suggests that vimentin might play 
a detrimental role in astrogliosis, as opposed to our previous 
understanding.
Research on miR-155 has provided insight into another possi-
bility for functional recovery from SCI. The miR-155 is normally 
upregulated in most leukocytes; it is also upregulated during 
SCI, contributing to the inflammatory destruction of the spinal 
cord. However, in miR-155 knockout mice, Basso Mouse Scale 
locomotor scores have been found to be higher 6 weeks after SCI 
compared with control groups. In addition, miR-155 knockout 
mice also expressed significantly lower levels of IL-17–express-
ing T cells, suggesting that miR-155 has a direct effect on Th17 
cell proliferation after SCI via the regulation of Janus-associated 
kinase/signal transducer and activator of transcription (JAK/
STAT) signaling by the suppressor of cytokine signaling 1 gene, 
SOCS1 (Table 1; Figure 7) (45, 46).
Spinal cord injury is often associated with severe pain 
syndrome. Therefore, careful consideration should be given to 
optimal pain treatment of patients with SCI, as 1 mode in par-
ticular leads to decreased motor recovery and increased chronic 
pain (30). In their study of morphine delivery and SCI, Strickland 
FiGURe 8 | Pain regulation with miRNA expression after SCi. 
Downregulation of miR-218 and miR-195, in addition to upregulation of 
miR-103, lead to decreases in neuropathic pain after SCI. CACNA1C, 
calcium channel, voltage gated, L-type, alpha-1 C; CACNA2D1, calcium 
channel voltage gated, L-type, alpha-2 delta-1; CACNB1, calcium channel, 
voltage gated, L-type, beta-1; IL1B, interleukin 1 beta; JAK, Janus kinase; 
STAT3, signal transducer and activators of transcription 3; SOCS3, supressor 
of cytokine signaling 3; TNF, tumor necrosis factor. Used with permission 
from Barrow Neurological Institute, Phoenix, AZ, USA.
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et al. noticed that acute administration of morphine correlated 
to these effects, potentially via the expression of miRNA, includ-
ing miR-21 and 146 (30). The miR-21 and 146 expressions were 
elevated by morphine. However, the rats experienced significant 
dysregulation of miR-21 and decreased motor function up to 
15 days after SCI recovery. These results may be attributable to 
morphine-induced inflammation. They further suggest that the 
effects of miR-21 on SCI recovery are time-sensitive and must 
be regulated beyond the acute stages of SCI, both to optimize 
the beneficial effects of miR-21 and to minimize its deleterious 
effects.
Pain
Increasing evidence over the past decade has suggested that 
miRNAs play a significant role in regulating both inflammatory 
and neuropathic pain following SCI (18, 29, 32–34, 49, 79–87). 
One of the major objectives in identifying miRNA sequences that 
influence pain modulation is to manipulate them for therapeutic 
uses. Although many miRNA sequences have already been found 
to influence chronic pain at the site of the lesion and in higher 
cortical structures, only a few miRNA sequences have been 
modulated and have been confirmed to have a therapeutic effect 
(33, 34, 49, 83, 86, 87).
In 2016, Li and Zhao demonstrated that miR-218 expres-
sion is consistent with neuropathic pain symptoms in rats 
with compressive spinal cord injuries (52). When miR-218 
was downregulated in rats, pain behavior and inflammation 
decreased. The authors hypothesize that miR-218 acts by 
inhibiting the JAK/STAT3 pathway by influencing the expres-
sion of the suppressor of the cytokine signaling 3 gene, SOCS3 
(Table  1; Figure  8) (52). In 2011, Favereaux et  al. identified 
miR-103 as regulating three subunits of a L-type voltage-gated 
calcium channel named CaV1.2 (subunits alpha-1C, alpha-2 
delta-1, and beta-1 are encoded by CACNA1C, CACNA2D1, and 
CACNB1, respectively) in dorsal horn neurons. This regulation 
was found to be bidirectional: upregulation of miR-103 led 
to downregulation of each subunit, and vice  versa (Table  1; 
Figure 8) (33). This finding was significant because an earlier 
study had already established a strong connection between the 
CaV1.2 protein and chronic pain, showing that a knockout of 
CaV1.2 protein would lead to complete reversal of long-term 
sensitization (32, 34). Favereaux et  al. also showed that the 
intrathecal application of miR-103 significantly relieved pain, 
thus establishing miR-103 as a strong candidate for the treat-
ment of chronic pain after SCI (33).
Another miRNA that has been linked to inflammatory pain 
after SCI is miR-195 (49). It was found to increase significantly 
after spinal nerve ligation, and it was also associated with the 
continuous release of proinflammatory cytokines, such as IL-1β 
and TNF-α (Figure 8). These researchers proposed that upregula-
tion of miR-195 leads to decreased autophagic activity and thus 
to increased neuroinflammation. In addition, upregulation of 
miR-195 was also positively linked with increased mechanical 
and cold sensitivity (49).
Both miR-103 and miR-195 have been shown to modulate 
chronic pain at the lesion site (33, 34, 49). Substantial evidence 
also shows that changes in miRNA expression in higher cortical 
structures are associated with inflammatory and neuropathic 
pain, indicating that pain relief therapies for SCI may not be 
restricted to the site of injury and nearby structures (83–87). 
For instance, miRNA expression changes substantially in both 
the prefrontal cortex and the hippocampus when stimulated by 
chronic pain (83, 86, 87).
Although the role of miRNAs in pain regulation is substantial, 
the exact mechanisms involved in pain sensation are very complex 
and require much further study (32). However, preliminary data 
suggest a promising role for the use of miRNAs as therapeutic 
agents for pain relief in many pathologic conditions, including 
SCI (32).
CONCLUSiON
Spinal cord injury is a serious and debilitating injury with limited 
treatment resources. After the initial injury to the spinal cord, 
numerous secondary pathophysiological events occur that con-
tribute to a major part of the total damage. Such secondary events 
include inflammation, apoptosis, ROS formation, and astrogliosis. 
In recent years, many studies have identified miRNAs as contribu-
tors and regulators of secondary injury, with most of the research 
providing specific mRNA targets for the miRNA involved. Not all 
miRNAs affect SCIs negatively, however. Some miRNAs appear 
to promote the beneficial aspects of the healing mechanisms of 
the body. For instance, miRNAs have been shown to promote 
neuroplasticity, axon regeneration and remyelination, neuron cell 
regeneration, and functional recovery. However, the underlying 
problem is that, in most cases, SCI causes both the overexpression 
of harmful miRNAs and the inhibition of beneficial miRNAs. 
Manipulating the expression of miRNAs after SCI might be a new 
therapeutic strategy for overcoming the lasting and detrimental 
effects of SCI, thereby giving clinicians better diagnostic tools and 
giving patients better outcomes. Overall, miRNAs may lead to 
an era of personalized medicine for individuals with SCIs. More 
research is mandated, and the expected results should provide 
new hope for better treatment of patients with SCIs.
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